The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma.
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Exelixis; Ipsen
 
Nizar M. Tannir
Stock and Other Ownership Interests - Amgen; BioCryst; Johnson & Johnson/Janssen; Merck; Spdr S&P Pharmaceuticals ETF; Surface Oncology; Vanguard Health Care
Honoraria - AstraZeneca/Merck; Bristol-Myers Squibb; Eisai; Exelixis; Intellisphere; Merck Sharp & Dohme; Nektar; Neoleukin Therapeutics; Oncorena
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck Sharp & Dohme; Nektar; Oncorena
Research Funding - Arrowhead Pharmaceuticals (Inst); Bristol Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Nektar (Inst); Novartis (Inst)
 
Peter Grell
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - SERVIER
 
Xin Gao
Consulting or Advisory Role - Arvinas; Bayer; Flare Therapeutics; Loxo/Lilly; PATHAI; PureTech; Silverback Therapeutics
Research Funding - ALX Oncology (Inst); Aprea Therapeutics (Inst); Aravive (Inst); Arvinas (Inst); Bayer (Inst); Exelixis (Inst); Harpoon therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Poseida therapeutics (Inst); Regeneron (Inst); Takeda (Inst); TopAlliance BioSciences Inc (Inst)
 
Ritesh R Kotecha
Consulting or Advisory Role - Eisai; Eisai; Guidepoint Inc; Guidepoint Inc
Research Funding - Allogene Therapeutics (Inst); Exelixis (Inst); Novartis (Inst); Pfizer (Inst); Takeda (Inst); Xencor (Inst)
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst)
 
Filippo G. De Braud
Honoraria - BMS; Incyte; Indena; IQVIA; Mattioli 1885; MCCann Health; Menarini; MSD; Pierre Fabre; Taiho Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Incyte; Pierre Fabre; Sanofi; Taiho Oncology
Speakers' Bureau - Ambrosetti; BMS; Dephaforum; Nadirex International; Novartis
Research Funding - AnHeart Therapeutics; Apollomics; AstraZeneca; BMS
Travel, Accommodations, Expenses - Sanofi
 
Shunji Takahashi
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer/EMD Serono (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
 
Alvin Wong
Honoraria - Johnson & Johnson/Janssen; Merck
Travel, Accommodations, Expenses - Ipsen; Novartis
 
Cristina Suárez
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Eisai; Ipsen; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Research Funding - AB Science (Inst); Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi Aventis GmbH (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Roche
 
Javier A Otero
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
Travel, Accommodations, Expenses - Novartis
 
Nicole Kundamal
Employment - Novartis
 
Xin Yang
Employment - Novartis
 
Sherif Sharaby
Employment - Novartis
 
Mike Roy
Employment - Novartis
Stock and Other Ownership Interests - Novartis; Novartis
 
Patrizia Barzaghi-Rinaudo
Employment - Novartis
 
Laurence Albiges
Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer